跳至主要内容
临床试验/EUCTR2007-005164-27-NL
EUCTR2007-005164-27-NL进行中(未招募)不适用

Botulinum toxin A intravesical injections in the treatment of Bladder Pain Syndrome/Interstitial Cystitis

research office urology VUmc0 个研究点目标入组 12 人开始时间: 2007年10月17日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • -Males and females aged 18 years, or older
  • -Written informed consent has been obtained from the subject
  • -Subject is able to fill in voiding diary and questionnaire
  • -Subject has BPS/IC for a period of at least 9 months prior to screening, as determined by patient history:
  • - patient had cystoscopy with hydrodistension and cold biopsy
  • - patient has used oral medication: anticholinergic, NSAID and
  • tricyclic antidepressant
  • - patient has used intravesical instillations with cystistat, or ura-cyst, or
  • bladder cocktails, or heparin, or oxybutinin
  • -Subject has Visual Analog Scale (VAS) more than 5
  • -Those subjects taking anticholinergic medication, NSAID or tricyclic antidepressant use a stable dose and they are willing to maintain the dose during the study
  • - Patients must be willing to use clean intermittent catheterization to empty the bladder
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Patient is pregnant, or patients who want to become pregnant during the study
  • - Patient has an active urinary tract infection or recurrent urinary tract infections
  • ( > 5 urinary tract infections a year)
  • - Patient has a chronic or bacterial prostatitis
  • - Patient has a vaginitis
  • - Patient has an active sexually transmitted diseases
  • - Patient has bladder stones or urolithiasis
  • - Patient has an urethra or bladder diverticulum
  • - Patient has carcinoma of the uterus, cervix, vagina, urethra or prostate
  • - Patient has carcinoma in situ / malignancy of the bladder
  • - Patient has chemical-, tuberculous- or radiation cystitis
  • - Patient has hemophilia or other clotting factor deficiencies or disorders that cause bleeding diatheses.
  • - Patient has any medical condition that may put the patient at increased risk with exposure to BTX-A including diagnosed myasthenia gravis, Eaton Lambert syndrome or amyotrophic lateral sclerosis
  • - Patient discontinued anticholinergic, NSAID or antidepressant medication for bladder pain < 14 days prior to screening
  • - Patient using intravesical instillations, or used it 4 weeks prior to screening
  • - Patient using neuromodulations devices for treatment of BPS/IC
  • - Patient is breastfeeding
  • - Patient has a post void residual volume above 200 ml
  • - Patients who will use neuromuscular blocking agents in the period of three days before until eight weeks after study treatment
  • - Patients who will use aminoglycoside antibiotics the period of three days before until eight weeks after study treatment

研究者

发起方
research office urology VUmc

相似试验